Immune Effect of Newcastle Disease Virus DNA Vaccine with C3d as a Molecular Adjuvant
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Newcastle disease is a serious infectious disease in the poultry industry. The commercial vaccines can only offer limited protection and some of them are expensive and need adjuvants. At present, DNA vaccines are widely used. However, the immune responses induced by DNA vaccines are too slow and low. Here, we constructed the transfer vectors with a different number of C3d as molecular adjuvants (n = 1, 2, 4, or 6), and the vectors were cloned into the optimal eukaryotic expression plasmid (pVAXI-optiF) that expressed the F gene of Newcastle disease virus (NDV), and named pVAXI-F(o)-C3d1, pVAXI -F(o)-C3d2, pVAXI-F(o)-C3d4, and pVAXI-F(o)-C3d6, respectively. Cell transfection test indicated that pVAXI-F(o)-C3d6 showed the highest expression. In vivo immunization showed that the chickens immunized with pVAXI-F(o)-C3d6 intramuscularly induced better immune responses than the chickens immunized with the other plasmids. The protective efficacy of pVAXI-F(o)-C3d6 was 80% after challenge with the highly virulent NDV strain F48E9. The results in this study showed that C3d6 could be used as a molecular adjuvant to quickly induce an effective immune response to control NDV.
Abstract
Newcastle disease is a serious infectious disease in the poultry industry. The commercial vaccines can only offer limited protection and some of them are expensive and need adjuvants. At present, DNA vaccines are widely used. However, the immune responses induced by DNA vaccines are too slow and low. Here, we constructed the transfer vectors with a different number of C3d as molecular adjuvants (n = 1, 2, 4, or 6), and the vectors were cloned into the optimal eukaryotic expression plasmid (pVAXI-optiF) that expressed the F gene of Newcastle disease virus (NDV), and named pVAXI-F(o)-C3d1, pVAXI -F(o)-C3d2, pVAXI-F(o)-C3d4, and pVAXI-F(o)-C3d6, respectively. Cell transfection test indicated that pVAXI-F(o)-C3d6 showed the highest expression. In vivo immunization showed that the chickens immunized with pVAXI-F(o)-C3d6 intramuscularly induced better immune responses than the chickens immunized with the other plasmids. The protective efficacy of pVAXI-F(o)-C3d6 was 80% after challenge with the highly virulent NDV strain F48E9. The results in this study showed that C3d6 could be used as a molecular adjuvant to quickly induce an effective immune response to control NDV.
참고문헌 (32)
- Steglich C, "Chimeric avian paramyxovirusbased vector immunization against highly pathogenic avian influenza followed by conventional Newcastle disease vaccination eliminates lack of protection from virulent ND virus", Trials Vaccinol, 3, pp.65~72 (2014)
- Miller PJ, "Identification of new sub-genotypes of virulent Newcastle disease virus with potential panzootic features", Infect. Genet. Evol, 29, pp.216~229 (2015)
- Hao HF, "Genetic variation in V gene of class II Newcastle disease virus", Infect. Genet. Evol, 37, pp.14~20 (2016)
- DiNapoli JM, "Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans", Vaccine, 27, pp.1530~1539 (2009)
- Wu Y, "Recombinant Newcastle disease virus (NDV", Anh-IL-2)expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy, 2016, pp.132, 24~30
- Morla S, "Molecular characterization of genotype XIIIb Newcastle disea se v irus f rom centra l India during 2006-2012: evidence of its panzootic potential", Microb. Pathog, 99, pp.83~86 (2016)
- Dimitrov KM, "Temporal, geographic, and host distribution of avian paramyxovirus 1 (Newcastle disease virus)", Infect. Genet. Evol, 39, pp.22~34 (2016)
- Dortmans JC, "The viral replication complex is associated with the virulence of Newcastle disease virus", J. Virol, 84, pp.10113~10120 (2010)
- Wang J, "Genomic characterizations of a Newcastle disease virus isolated from ducks in live bird markets in China", PLoS One, 11, pp.e0158771~ (2016)
- Liu XF, "Pathotypical and genotypical characterization of Newcastle disease virus isolated from outbreaks in chicken and goose flocks in some regions of China during 1985-2001", Arch. Virol, 148, pp.1387~1403 (2003)
- Nagai Y, "Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus", Virology, 72, pp.494~508 (1976)
- Cardenas-Garcia S, "Development of an improved vaccine evaluation protocol to compare the efficacy of Newcastle disease vaccines", Biologicals, 43, pp.136~145 (2015)
- Cardenas-Garcia S, "Effects of chicken interferon gamma on Newcastle disease virus vaccine immunogenicity", PLoS One, 11, pp.e0159153~ (2016)
- Wang G, "Non-thermal plasma for inactivated-vaccine preparation", Vaccine, 34, pp.1126~1132 (2016)
- Kim SH, "Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines", Viruses, 8, pp.2~15 (2016)
- Kumar S, "Newcastle disease virus outbreaks in India:time to revisit the vaccine type and strategies", Vaccine, 33, pp.3268~3269 (2015)
- Baxter D., "Active and passive immunity, vaccine types, excipients and licensing", Occup. Med, 57, pp.552~556 (2007)
- Xu GL, "Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant", Vaccine, 28, pp.7221~7227 (2010)
- Ramezanpour B, "Emergency deployment of genetically engineered veterinary vaccines in Europe", Vaccine, 34, pp.3435~3440 (2016)
- Tlaxca JL, "Live attenuated and inactivated viral vaccine formulation and nasal delivery:potential and challenges", Adv. Drug Deliv. Rev, 93, pp.56~78 (2015)
- Li L, "Molecular mechanisms for enhanced DNA vaccine immunogenicity", Expert Rev. Vaccines, 15, pp.313~329 (2016)
- Oreskovic Z, "Oil-based adjuvants delivered intradermally induce high primary IgG2 immune response in swine", Res. Vet. Sci, 114, pp.41~43 (2017)
- Crépeaux G, "Nonlinear dose-response of aluminium hydroxide adjuvant particles: selective low dose neurotoxicity", Toxicology, 375, pp.48~57 (2017)
- Buonavoglia D, "Long-term immunogenicity and protection against Mycoplasma agalactiae induced by an oil adjuvant vaccine in sheep", Res. Vet. Sci, 88, pp.16~19 (2010)
- Dempsey PW, "C3d of complement as a molecular adjuvant:bridging innate and acquired immunity", Science, 271, pp.348~350 (1996)
- Zhao K, "Synthesis, characterization and immune efficacy of LDH@SiO2nanoparticles with shell-core structure as a delivery carrier for Newcastle disease virus DNA vaccine", Int. J. Nanomedicine, 10, pp.2895~2911 (2015)
- Wang R, "Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites", Infect. Immun, 73, pp.2863~2872 (2005)
- Zhang Y, "The solvent at antigen-binding site regulated C3d-CR2 interactions through the C-terminal tail of C3d at different ion strengths:insights from molecular dynamics simulation", Biochem. Biophys. Acta, 1860, pp.2220~2231 (2016)
- Li GX, "Prime-boost immunization with HA", C3d DNA followed by a recombinant pseudorabies virus boost enhanced protective immunity against H3N2 swine influenza virus in mice, 2010, pp.88, 345~351
- Musa HH, "Cloning and expression of FimA-C3d recombinant protein", J. Genet. Eng. Biotechnol, 12, pp.55~59 (2014)
- Suradhat S, "Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization", Vet. Immunol. Immunopathol, 83, pp.79~92 (2001)
- Liu D, "Cloning of a gene fragment encoding chicken complement component C3d with expression and immunogenicity of Newcastle disease virus F gene-C3d fusion protein", Avian Pathol, 37, pp.477~485 (2008)